Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 7Salivary Gland Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1

Interventions

pembrolizumab 128Carboplatin 126Pemetrexed 106Cisplatin 79Paclitaxel 60osimertinib 54Nivolumab 53Docetaxel 52durvalumab 48Specimen Handling 40Magnetic Resonance Spectroscopy 36Gemcitabine 36Radiosurgery 29atezolizumab 27130-nm albumin-bound paclitaxel 27Cetuximab 26Radiotherapy 23Ipilimumab 22Drug Therapy 22cemiplimab 20Bevacizumab 20amivantamab 18Taxes 16Ramucirumab 13tislelizumab 12alectinib 12Radiation 12Biopsy 12lazertinib 11Oxaliplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Glutamate Carboxypeptidase II × 90 days × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡